X
<

Who's Watching Alexion Now?

PART:
1 2 3 4
Part 4
Who's Watching Alexion Now? PART 4 OF 4

How Strensiq Could Boost Alexion’s Long-Term Growth

Strensiq revenue trends

In 2Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of ~$83 million, which was ~84% higher YoY (year-over-year) and ~12% higher QoQ (quarter-over-quarter). In 1H17, Strensiq reported revenues of ~$157 million, compared with $78 million in 1H16.

How Strensiq Could Boost Alexion’s Long-Term Growth

Interested in ALXN? Don't miss the next report.

Receive e-mail alerts for new research on ALXN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Geographical revenue trends

In 1H17, in the US, Europe, Asia-Pacific, and the rest of the world, Strensiq reported revenues of ~$133 million, ~$14 million, ~$8 million, and ~$2 million, respectively, compared with ~$67 million, ~$4 million, ~$6 million, and ~$1 million, in 1H16.

In 2Q17, in the US, Europe, Asia-Pacific, and the rest of world, Strensiq reported revenues of ~$70 million, ~$8 million, ~$4 million, and ~$1 million, respectively.

Notably, the iShares Core S&P 500 ETF (IVV) has ~0.15% of its total portfolio holdings in ALNX.

About Strensiq

The Strensiq (asfotase alfa) injection is used for the treatment of perinatal and infantile and juvenile-onset HPP (hypophosphatasia).

In July 2017, Alexion established a funding agreement with NICE (National Institute for Health and Care Excellence) and the NHS (National Health Service) in England to help pediatric-onset HPP patients in England access Strensiq therapy, regardless of age. The funding agreement is expected to strengthen the position of Strensiq in England, as Strensiq has continued to gain strength in the US, Germany, and Japan.

Alexion’s peers in rare disease drugs market include Amgen (AMGN), Novartis (NVS), Pfizer (PFE), BioMarin Pharmaceuticals, Sanofi Genzyme, and Vertex Pharmaceuticals.

X

Please select a profession that best describes you: